

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/112719 A3

(51) International Patent Classification⁷: C07D 403/12,
A61K 31/416

(74) Agents: LEVY, David, J. et al.; c/o GlaxoSmithKline,
Corporate Intellectual Property Dept, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number:
PCT/US2004/019692

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/479,753 19 June 2003 (19.06.2003) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19101
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DREWRY, David**,
Harold [US/US]; c/o GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC (US).
EVANS, Brian [GB/GB]; c/o Glaxo Medicines R & D
Centre, Gunnels Wood Road, Stevenage, Hertfordshire,
SG1 2NY (GB). **GOODMAN, Krista, B.** [US/US]; c/o
GlaxoSmithKline, 709 Swedeland Road, King of Prussia,
PA 19406 (US). **GREEN, Darren, Victor, Steven**
[GB/GB]; c/o Glaxo Medicines R & D Centre, Gunnels
Wood Road, Stevenage, Hertfordshire, SG1 2NY (GB).
JUNG, David, Kendall [US/US]; c/o GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle
Park, NC 27709 (US). **LEE, Denis** [US/US]; c/o GlaxoSmithKline,
709 Swedeland Road, King of Prussia, PA 19406 (US).
STAVENGER, Robert, A. [US/US]; c/o GlaxoSmithKline,
709 Swedeland Road, King of Prussia, PA 19406 (US).
WADMAN, Sjoerd, Nicolaas [CH/US]; c/o GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
7 April 2005

(48) Date of publication of this corrected version:
26 May 2005

(15) Information about Correction:
see PCT Gazette No. 21/2005 of 26 May 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: The present invention relates to indazolo-tetrahydropyrimidine-carboxamide derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such indazolo-tetrahydropyrimidine-carboxamide derivatives are useful in the treatment of diseases associated with inappropriate ROCK-1 kinase.

WO 2004/112719 A3